A venture capital firm, with a single LP, has offices in the US. The group looks to make growth-stage investments in the form of preferred equity, ranging from $2M-$7M initially, with additional capital reserved for follow-on financings, typically up to $15M over the life of the investment. The firm usually leads rounds, but is also open to syndicating with other investors. The firm looks to do 3-4 deals a year, and invests in U.S. and Canadian companies. Prospective companies may have some business overseas as long as they are headquartered in the U.S. or Canada.
The firm solely invests in healthcare companies, and is open to any healthcare companies that do not require FDA approval for their product/service. Some of the firm’s recent healthcare investments include a predictive and interventive artificial intelligence platform for health plans and risk bearing providers as well as a next generation drug spend savings platform for employers and health plans.
The firm typically looks for growing companies with a run rate of at least $1M or a signed contract that would put them at a $1M run rate. The firm has no strict requirements in terms of management team, and oftentimes works with first-time entrepreneurs. The firm looks to take a board seat along with an investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment